|
31 October 2001
De Novo Pharmaceuticals Ltd. and ChemOvation
Ltd. announce drug research collaboration
De Novo Pharmaceuticals Ltd and ChemOvation
Ltd are pleased to announce that they have entered into a collaborative
agreement for the provision of synthetic chemistry services directed
towards certain De Novo drug discovery targets. Under the terms
of the collaboration, full details of which have not been disclosed,
ChemOvation will provide synthetic chemistry services and expertise
for the generation of low molecular weight drug like compounds arising
from De Novo's proprietary computational modelling for a number
of targets currently within De Novo's discovery portfolio.
Dr Alan Stuttle, Chief Executive Officer of
ChemOvation commented, "We are delighted at having been chosen
to support De Novo in its quest for novel drug entities arising
from its proprietary computational software. ChemOvation is able
to offer its partners a high level of expertise in many aspects
of the drug discovery process. We look forward to a fruitful collaboration
with De Novo in supporting the development of their drug candidates."
Dr David Bailey, Chief Executive Officer of
De Novo, added, "Our discovery portfolio concentrates on key
target areas where there is an urgent need for high quality leads
with potential for rapid progression into development. As we move
forwards, we are building a network of efficient and flexible collaborations
with companies such as ChemOvation through which to augment our
internal capabilities in drug discovery."
De Novo Pharmaceuticals Ltd
De Novo Pharmaceuticals Ltd based in Cambridge
UK, uses its proprietary computational software for drug design
to create novel, patentable lead molecules as candidates for drug
development against both enzyme and receptor based targets. De Novo's
proprietary algorithms can convert ligand information or protein
structure information in combination with medicinal chemistry rapidly
into new chemical designs, maximising value within a pharmaceutical
partner's research portfolio. In addition, De Novo applies its leading
in silico drug discovery capabilities to its own in-house research
programmes, generating high value lead candidates available for
licensing.
ChemOvation Ltd
ChemOvation was established in 1998 to provide
compound libraries to collaborators. Since its inception, the company
has expanded to offer many aspects of the drug discovery process.
ChemOvation collaborates with its clients to achieve drug candidate
realisation by bringing together molecular modelling, medicinal
chemistry, compound synthesis, primary screening, early stage in
vitro toxicology and ADME. It configures expert teams to undertake
projects including hit expansion and lead optimisation that are
designed to give the strongest possible chance of drug discovery
and lead generating potential.
Further Information:
Dr Steven Beasley
Chief Operating Officer
De Novo Pharmaceuticals Ltd
St Andrews House
59 St Andrews Street
Cambridge, CB2 3DD
United Kingdom
Phone +44 (0)1223 488888
Fax +44 (0)1223 488899
Email: steve.beasley@denovopharma.com
Website: www.denovopharma.com
Dr Keith Menear
ChemOvation Ltd
Foundry Lane
Horsham
West Sussex, RH13 5PX
United Kingdom
Phone +44 (0)1403 248844
Fax +44 (0)1403 248855
Email:keith.menear@chemovation.com
|
